OMERS ADMINISTRATION Corp Sells 16,600 Shares of Hims & Hers Health, Inc. $HIMS

OMERS ADMINISTRATION Corp lessened its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 34.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,500 shares of the company’s stock after selling 16,600 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Hims & Hers Health were worth $1,570,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after purchasing an additional 227 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the period. True Vision MN LLC raised its holdings in Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock valued at $467,000 after buying an additional 328 shares during the last quarter. WealthPlan Investment Management LLC boosted its position in Hims & Hers Health by 2.6% during the 2nd quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock worth $818,000 after buying an additional 410 shares during the period. Finally, Securian Asset Management Inc. boosted its position in Hims & Hers Health by 2.8% during the 2nd quarter. Securian Asset Management Inc. now owns 14,931 shares of the company’s stock worth $744,000 after buying an additional 411 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on HIMS shares. Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday. Truist Financial cut their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. UBS Group set a $32.00 price target on Hims & Hers Health in a research report on Tuesday, November 4th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $45.27.

Hims & Hers Health Trading Down 3.2%

NYSE HIMS opened at $36.32 on Wednesday. Hims & Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The business has a 50 day simple moving average of $46.76 and a 200 day simple moving average of $50.14. The stock has a market capitalization of $8.27 billion, a P/E ratio of 67.26, a P/E/G ratio of 7.47 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same period last year, the business earned $0.32 EPS. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its board has initiated a stock repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to reacquire up to 3% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 23,187 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $36.81, for a total value of $853,513.47. Following the completion of the sale, the chief financial officer directly owned 70,232 shares in the company, valued at $2,585,239.92. This trade represents a 24.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Soleil Boughton sold 2,637 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $42.53, for a total value of $112,151.61. Following the completion of the sale, the insider directly owned 155,856 shares of the company’s stock, valued at $6,628,555.68. The trade was a 1.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 616,431 shares of company stock valued at $32,924,482. Corporate insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.